Search

Displaying results 2771 - 2780 of 4344 in total
  1. Drug

    ILY101

    go.drugbank.com/drugs/DB05059
    Investigational

    ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate.

  2. Drug

    ACR-16

    go.drugbank.com/drugs/DB05371
    Investigational

    ACR-16 is under investigation by NeuroSearch.

  3. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008.

  4. Drug

    Bufexamac

    go.drugbank.com/drugs/DB13346
    ApprovedWithdrawn

    Bufexamac was also withdrawn by the EMA in April 2010.

  5. Drug

    Belladonna

    go.drugbank.com/drugs/DB13913
    Approved

    The name "belladonna" originates from the Italian words "beautiful woman" and the historical use of herb eye-drops by women to dilate the pupils of the eyes for aesthetic purposes.

  6. Drug

    PH-284

    go.drugbank.com/drugs/DB05452
    Experimental

    This binding produces neural impulses that are transmitted by specific pathways to the hypothalamic centre that directly and rapidly affect brain function. … PH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of appetite and cachexia in cancer and AIDS patients.

  7. Drug

    Oxyquinoline

    go.drugbank.com/drugs/DB11145
    ApprovedInvestigationalVet approved

    Oxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.

  8. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  9. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  10. Drug

    TAK-751S

    go.drugbank.com/drugs/DB06432
    Investigational

    TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia coli_.[A260296]